Email: info@apollotherapeutics.comTranslating innovative science into therapeutic potential

Latest Apollo Projects

A novel mechanism for inhibition of CK2(alpha) in oncology

By Richard Butt

A novel mechanism for inhibition of CK2(alpha) in oncology

a collaboration with Dr Marko Hyvonen and Prof David Spring, University of Cambridge

Dr Marko Hyvonen from Department of Biochemistry and Prof David Spring from the Department of Chemistry, University of Cambridge have used a combination of fragment-based screening and structural biology to discover and characterise a unique small molecule binding pocket adjacent to the ATP-binding site of CK2α and a variety of fragments binding into this site.  Based on this research, Apollo and University of Cambridge teams are now collaborating to run a structurally-enabled small molecule drug discovery project to exploit the novel binding pocket and the active fragments to deliver potent and selective inhibition of CK2a.


|